
[1] ASCO #727-2000 
Identification of Biochemical Parameters That Predict the Onset of Severe Toxicities in Patients Treated with ET-743.   ET 743 Phase I group. 

[2] ASCO #1407-2001 
ET-743 is an Active Drug in Adult Soft-Tissue Sarcoma (STS): a STBSG-EORTC Phase II Trial. Axel Le Cesne, Jean-Yves Blay, Ian Judson, Allan Van Oosterom, Jaap 
            Verweij, John Radford, Paul Lorigan, Sjoerd Rodenhuis, Eugenio 
            Donato Di Paola, Martine Van Glabbeke, Jose Jimeno, Ole Nielsen, 
            Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, 
            Lyon, France; Royal Marsden Hospital, London, UK; U.Z. Gasthuisberg, 
            Leuven, Belgium; A.Z. Rotterdam, Rotterdam, Netherlands; Christie 
            Hospital, Manchester, UK; Weston Park Hospital, Sheffield, UK; 
            Antoni Van Leeuwenhoekhuis, Amsterdam, Netherlands; EORTC, 
            Bruxelles, Belgium; Pharma-Mar, Madrid, Spain; Aarhus 
            Kommunehospital, Aarhus, Denmark.

[3] Med Res Rev 2000 Jan;20(1):1-27
Antitumor compounds from tunicates.
Rinehart KL.
Department of Chemistry, University of Illinois, 454 Roger Adams Laboratory, 600
So. Mathews Avenue, Urbana, Illinois 61801, USA.
&&url PMID: 10608919

[4] ASCO #2177-2000  Ecteinascidin (ET-743) Shows Promising Activity in Distinct Populations
of Sarcoma Patients: Summary of 3 U.S.-Based Phase II Trials. George D.
Demetri, Michael Seiden, Rocio Garcia-Carbonero, Jeffrey Supko, David
Harmon, Geraldine Goss, Lucette Robinson, Priscilla Merriam, Alison
Waxman, M T Quigley, Jose Jimeno, David P Ryan, Dana-Farber Cancer
Institute and Harvard Medical Sch, Boston, MA; MA Gen Hosp
(Dana-Farber/Partners CancerCare), Boston, MA; Dana Farber Cancer
Institute, Boston, MA; PharmaMar, Inc, Cambridge, MA. 

[5] ASCO #1449-2001 
Ecteinascidin (ET-743) Given as a 24 Hour (H) Intravenous Continuous Infusion (IVCI) Every 3 Weeks: Results of a Phase II Trial in Patients (pts) with Pretreated Soft Tissue Sarcomas (PSTS). 
            Alejandro Yovine, Mauricio Riofrío, Etienne Brain, Jean Yves Blay, C 
            Kahatt, Suzette Delaloge, Lucille Beautier, P Cottu, José Jimeno, 
            Esteban Cvitkovic, Jean Louis Misset, Hopital Paul Brousse, Paris, 
            France; Institut Gustave Roussy, Paris, France; Centre René 
            Huguenin, Paris, France; Centre Leon Berard, Lyon, France; Cvitkovic 
            Associés Consultants, Paris, France; Hopital Saint Louis, Paris, 
            France; Pharma Mar, Tres Cantos, Spain.

[6] Anticancer Drug Des 1999 Jun;14(3):179-86
Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.  Bonfanti M, La Valle E, Fernandez Sousa Faro JM, Faircloth G, Caretti G, Mantovani R, D'Incalci M.  Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. 
&&url PMID: 10500494

[7] Br J Cancer 1996 Apr;73(8):875-83  
Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.  
Garcia-Rocha M, Garcia-Gravalos MD, Avila J.    
Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid, Spain. 
&&url PMID: 8611420

[8] Biochemistry 1996 Oct 15;35(41):13303-9     
DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor  
groove by ecteinascidin 743, a potent antitumor compound from the Caribbean
tunicate Ecteinascidia turbinata.
Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW.
Laboratory of Molecular Pharmacology, National Cancer Institute, National
Institutes of Health, Bethesda, Maryland 20892-4255, USA.
&&url PMID: 8873596

[9] ASCO #1406-2001 
Ecteinascidin-743 (ET-743) Induces Durable Responses and Promising 1-Year Survival Rates in Soft Tissue Sarcomas (STS): Final Results of Phase II and Pharmacokinetic Studies in the U.S.A.     from Dana Farber and MSKCC
             
10.Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.
Zewail-Foote M, Hurley LH.
Department of Chemistry and Biochemistry and College of Pharmacy, Drug Dynamics
Institute, The University of Texas at Austin, Austin, Texas 78712, USA.
&&url PMID: 10411470 
